Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

BACKGROUND: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IB...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Boltin, Doron, Perets, Tsachi Tsadok, Shporn, Einav, Aizic, Shoshana, Levy, Sigal, Niv, Yaron, Dickman, Ram
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201689/
https://ncbi.nlm.nih.gov/pubmed/25319626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-014-0049-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars